Odactra™ House Dust Mite – New drug approval
March 1, 2017 – The FDA announced the approval of ALK’s Odactra House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) allergen extract, as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus HDMs, or skin testing to licensed HDM allergen extracts.
Top